USD 10.27
(7.65%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 209.68 Million USD | 31.48% |
2022 | 159.48 Million USD | -9.18% |
2021 | 175.6 Million USD | -37.73% |
2020 | 282.02 Million USD | 75.19% |
2019 | 160.98 Million USD | 84.07% |
2018 | 87.46 Million USD | -61.6% |
2017 | 227.77 Million USD | 169.24% |
2016 | 84.6 Million USD | 22.08% |
2015 | 69.29 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 207.73 Million USD | -0.93% |
2024 Q2 | 214.45 Million USD | 3.24% |
2023 Q3 | 187.33 Million USD | 6.48% |
2023 Q2 | 175.94 Million USD | 14.78% |
2023 Q4 | 209.68 Million USD | 11.93% |
2023 Q1 | 153.28 Million USD | -3.89% |
2023 FY | 209.68 Million USD | 31.48% |
2022 Q2 | 164.05 Million USD | 6.94% |
2022 Q4 | 159.48 Million USD | -2.46% |
2022 Q1 | 153.41 Million USD | -12.64% |
2022 FY | 159.48 Million USD | -9.18% |
2022 Q3 | 163.49 Million USD | -0.34% |
2021 Q1 | 133.9 Million USD | -52.52% |
2021 FY | 175.6 Million USD | -37.73% |
2021 Q4 | 175.6 Million USD | 49.05% |
2021 Q3 | 117.81 Million USD | -11.9% |
2021 Q2 | 133.72 Million USD | -0.14% |
2020 FY | 282.02 Million USD | 75.19% |
2020 Q3 | 180.68 Million USD | 19.71% |
2020 Q4 | 282.02 Million USD | 56.09% |
2020 Q1 | 151.54 Million USD | -5.86% |
2020 Q2 | 150.94 Million USD | -0.4% |
2019 Q4 | 160.98 Million USD | -2.8% |
2019 Q2 | 161.6 Million USD | 11.01% |
2019 FY | 160.98 Million USD | 84.07% |
2019 Q1 | 145.57 Million USD | 66.44% |
2019 Q3 | 165.62 Million USD | 2.49% |
2018 Q3 | 88.41 Million USD | 5.25% |
2018 Q1 | 75.41 Million USD | -66.89% |
2018 FY | 87.46 Million USD | -61.6% |
2018 Q4 | 87.46 Million USD | -1.08% |
2018 Q2 | 83.99 Million USD | 11.39% |
2017 FY | 227.77 Million USD | 169.24% |
2017 Q3 | 94.51 Million USD | -55.66% |
2017 Q2 | 213.14 Million USD | 0.0% |
2017 Q1 | - USD | -100.0% |
2017 Q4 | 227.77 Million USD | 140.99% |
2016 Q4 | 84.6 Million USD | 0.0% |
2016 FY | 84.6 Million USD | 22.08% |
2015 FY | 69.29 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 77.878% |
Embecta Corp. | 2.03 Billion USD | 89.702% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 55.544% |
Dynavax Technologies Corporation | 375.02 Million USD | 44.087% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 68.267% |
Pacira BioSciences, Inc. | 704.25 Million USD | 70.226% |
PainReform Ltd. | 2.69 Million USD | -7692.159% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | -27.932% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -3315.32% |
SCYNEXIS, Inc. | 55.45 Million USD | -278.155% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -2180.046% |
Cosmos Health Inc. | 30.25 Million USD | -593.122% |
Journey Medical Corporation | 56.49 Million USD | -271.134% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -3315.32% |
Safety Shot Inc | 3.89 Million USD | -5287.58% |
Alpha Teknova, Inc. | 38.55 Million USD | -443.921% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | -53.2% |
Bright Green Corporation | 6.43 Million USD | -3156.969% |
Procaps Group, S.A. | 462.06 Million USD | 54.62% |
Theratechnologies Inc. | 98.63 Million USD | -112.58% |
Harrow Health, Inc. | 241.75 Million USD | 13.264% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -2294.781% |
Biofrontera Inc. | 23.13 Million USD | -806.206% |
DURECT Corporation | 30.4 Million USD | -589.624% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 56.984% |
Cronos Group Inc. | 43.73 Million USD | -379.437% |
OptiNose, Inc. | 194.33 Million USD | -7.9% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 74.346% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -332.835% |
RedHill Biopharma Ltd. | 20.97 Million USD | -899.551% |
Organogenesis Holdings Inc. | 181.36 Million USD | -15.618% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -5458.843% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -299.281% |
Radius Health, Inc. | 804.29 Million USD | 73.929% |
Universe Pharmaceuticals INC | 13.75 Million USD | -1424.516% |
ProPhase Labs, Inc. | 42.54 Million USD | -392.871% |
Phibro Animal Health Corporation | 725.54 Million USD | 71.099% |
Procaps Group S.A. | 462.06 Million USD | 54.62% |
Alvotech | 1.88 Billion USD | 88.862% |
TherapeuticsMD, Inc. | 14.02 Million USD | -1395.414% |
Viatris Inc. | 27.21 Billion USD | 99.23% |
Rockwell Medical, Inc. | 30.88 Million USD | -578.994% |
Aytu BioPharma, Inc. | 90.37 Million USD | -132.009% |
SIGA Technologies, Inc. | 57.97 Million USD | -261.671% |
Tilray Brands, Inc. | 892.11 Million USD | 76.496% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 4.601% |
Shineco, Inc. | 47.6 Million USD | -340.503% |
PetIQ, Inc. | 645.22 Million USD | 67.502% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -95424.163% |
Incannex Healthcare Limited | 5.83 Million USD | -3496.69% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 79.43% |
Alimera Sciences, Inc. | 107.35 Million USD | -95.323% |
Silver Spike Investment Corp. | 3 Million USD | -6866.737% |
Assertio Holdings, Inc. | 148.41 Million USD | -41.283% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -10959.645% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -883.718% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -2884.443% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2369.657% |
Avadel Pharmaceuticals plc | 173.38 Million USD | -20.936% |
Hempacco Co., Inc. | 18.82 Million USD | -1014.029% |
Talphera, Inc. | 6.29 Million USD | -3233.657% |
Alvotech | 1.88 Billion USD | 88.862% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -21.487% |
Lantheus Holdings, Inc. | 835.25 Million USD | 74.896% |
Currenc Group, Inc. | 177.67 Million USD | -18.017% |
Kamada Ltd. | 109.96 Million USD | -90.68% |
Indivior PLC | 1.95 Billion USD | 89.254% |
Evoke Pharma, Inc. | 9.64 Million USD | -2073.354% |
Flora Growth Corp. | 17.22 Million USD | -1117.553% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -2369.657% |
HUTCHMED (China) Limited | 536.38 Million USD | 60.907% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 75.994% |
Akanda Corp. | 12.66 Million USD | -1555.134% |